Health AdultsWeF2NCT07606885
Westlake Frequent-sampling Cohort 2
An observational study of Health Adults and Stability of Microbiome, run by Westlake University at 1 site in China.
Trial summary
This observational follow-up study extends a previously completed 15-day intensive longitudinal study (WeF) of the gut microbiome in healthy adults. The objective of WeF2 is to characterize the long-term stability and dynamics of the gut and oral microbiota in the same cohort across multiple timescales, and to… Read more about this study
- Who is it for?
- Ages 18 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Health Adults, Stability of Microbiome
- How many people
- 20 participants
- Where
- 1 siteChina
- Study dates
- 15 Feb 2026to 31 Dec 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: Healthy young adults residing in Hangzhou
Who may be able to join
- Participants reside in Hangzhou
Who cannot join
- Refusing or unable to give informed consent
- Participants with chronic gastrointestinal diseases and take daily relevant medications
- Participants with metabolic diseases including diabetes, hypertension and cardiovascular diseases (CVD)
- Participants with craniocerebral trauma, cancer, liver disease, kidney disease, or other critical illness, or history of operation or medication
- Participants with bulimia nervosa, post-traumatic stress disorder (PTSD), chronic anxiety and depression or other critical neuronal disorder or history of relevant medication
- Being or to be pregnant or lactating.
- Participants with history of alcohol or drug addiction, or smoke above 15 cigarettes per day
- Concurrently participating other clinical trials.
Trial locations and contacts
1 site in 1 country.
About this study
This observational follow-up study extends a previously completed 15-day intensive longitudinal study (WeF) of the gut microbiome in healthy adults. The objective of WeF2 is to characterize the long-term stability and dynamics of the gut and oral microbiota in the same cohort across multiple timescales, and to determine whether the day-to-day variability patterns observed at baseline persist over months and years. Participants who completed the WeF baseline protocol will be invited to attend periodic follow-up visits for low-frequency biospecimen collection and to repeat the original 15-day high-frequency sampling protocol at planned intervals, beginning approximately six months after the WeF baseline and continuing at extended intervals thereafter. By combining sparse routine sampling with recurring high-density sampling windows, the study aims to distinguish the stable core microbiome from transient and seasonal fluctuations, to track gradual community shifts under free-living conditions, and to further explore relationships among microbiome dynamics, dietary intake, and host glycemic regulation over an extended observation period.
Read the detailed description
WeF2 is a non-interventional, observational follow-up study conducted in the cohort of healthy adult volunteers who completed the WeF baseline protocol. The study is designed to extend the temporal resolution of the original investigation from a single 15-day window to a multi-year horizon that interleaves low- and high-frequency sampling phases, allowing direct comparison of within-subject microbiome dynamics across short, medium, and long timescales. The overall follow-up duration is open-ended in design, with the intention that participants may continue to contribute to the cohort for as long as they remain willing and eligible.
The study is organized around two complementary sampling modes that recur throughout the follow-up period.
The routine follow-up mode consists of brief periodic visits, planned at approximately monthly intervals during the intervals between intensive sampling windows. At each routine visit, a single stool sample and a saliva sample are collected for microbial sequencing and functional evaluation, together with basic health and lifestyle information covering items such as recent dietary patterns, medication and supplement use, antibiotic exposure, illness, travel, and notable lifestyle changes since the previous visit. The exact content and cadence of these routine visits may be adjusted over the course of the study to reflect emerging scientific priorities, participant burden considerations, and operational feasibility, while preserving the core objective of capturing gradual community shifts and flagging transient perturbations occurring between intensive windows.
The intensive sampling mode replicates the original 15-day WeF protocol in full and is scheduled to recur at planned long-interval timepoints. The first intensive follow-up window is conducted approximately six months after completion of the WeF baseline; a second intensive window is planned approximately six months after the first (i.e., approximately one year after the WeF baseline); and additional intensive windows may be conducted at extended intervals thereafter as the cohort is maintained. Each intensive window involves daily collection of stool and saliva samples; collection of representative samples from meals consumed during the period for DNA sequencing of food sources, providing an objective record of dietary intake; and continuous blood glucose monitoring via a wearable CGM device throughout the 15 days. By holding the intensive protocol methodologically consistent with the WeF baseline, each intensive window produces a directly comparable dataset at the level of individual taxa, community structure, dietary signatures, and glycemic responses.
Routine follow-up visits continue in the periods between intensive windows, including after each intensive window has concluded, so that the cohort is observed under a continuous low-frequency framework punctuated by recurring high-frequency snapshots.
Integrating these sampling modes produces a longitudinal dataset that supports several complementary analyses: characterization of the temporal stability of the core microbiota across months and years; assessment of whether the magnitude and structure of day-to-day variability observed at baseline are reproducible at later timepoints; differentiation of intra-individual fluctuations from inter-individual differences across an expanded observation period; identification of seasonal or longer-cycle patterns in microbiome composition; and exploration of how dietary inputs and glycemic patterns relate to microbial dynamics on daily, monthly, and annual scales.
To ensure data integrity and participant safety, the study is overseen by a Data and Safety Monitoring Board and adheres to ethical standards approved by the Westlake University Ethics Committee, consistent with the framework established for the WeF baseline study.
- Conditions
- Health Adults, Stability of Microbiome
- Keywords
- Microbiome
What is being measured
The primary outcome is the main question the study is designed to answer.
Gut microbiome
Description: Using qPCR, metagenomics, metabolomics, proteomics, and culturomics, we quantified the composition and absolute abundance of the gut microbiota and characterized its short-term and long-term dynamics.
Measured: 3 years
Secondary outcomes (1)
Continuous blood glucose change over 2 weeks
Glucose levels are assessed by continuous glucose monitoring over 2 weeks.
Measured: Two weeks after enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 May 2026
- Study start15 Feb 2026
- Primary completion8 May 2027 (estimated)
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Health AdultsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Westlake University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Ju-Sheng Zheng, PhD, Principal investigator, Westlake University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07606885
- Sponsor's protocol ID
- 20260420ZJS001
- Acronym
- WeF2
- Status last verified
- Aug 2026
- First submitted
- 19 May 2026
- Last updated
- 29 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Westlake Frequent-sampling Cohort 2
- ClinicalTrials.gov ID
- NCT07606885
- Acronym / sponsor ID
- WeF2 / 20260420ZJS001
- Conditions
- Health Adults, Stability of Microbiome
- Keywords
- Microbiome
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Westlake UniversityUniversity, hospital or other
- Study start
- 15 Feb 2026 (actual)
- Primary completion
- 8 May 2027 (estimated)
- Study completion
- 31 Dec 2030 (estimated)
- First posted
- 26 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This observational follow-up study extends a previously completed 15-day intensive longitudinal study (WeF) of the gut microbiome in healthy adults. The objective of WeF2 is to characterize the long-term stability and dynamics of the gut and oral microbiota in the same cohort across multiple timescales, and to determine whether the day-to-day variability patterns observed at baseline persist over months and years. Participants who completed the WeF baseline protocol will be invited to attend periodic follow-up visits for low-frequency biospecimen collection and to repeat the original 15-day high-frequency sampling protocol at planned intervals, beginning approximately six months after the WeF baseline and continuing at extended intervals thereafter. By combining sparse routine sampling with recurring high-density sampling windows, the study aims to distinguish the stable core microbiome from transient and seasonal fluctuations, to track gradual community shifts under free-living conditions, and to further explore relationships among microbiome dynamics, dietary intake, and host glycemic regulation over an extended observation period.
Detailed description
WeF2 is a non-interventional, observational follow-up study conducted in the cohort of healthy adult volunteers who completed the WeF baseline protocol. The study is designed to extend the temporal resolution of the original investigation from a single 15-day window to a multi-year horizon that interleaves low- and high-frequency sampling phases, allowing direct comparison of within-subject microbiome dynamics across short, medium, and long timescales. The overall follow-up duration is open-ended in design, with the intention that participants may continue to contribute to the cohort for as long as they remain willing and eligible.
The study is organized around two complementary sampling modes that recur throughout the follow-up period.
The routine follow-up mode consists of brief periodic visits, planned at approximately monthly intervals during the intervals between intensive sampling windows. At each routine visit, a single stool sample and a saliva sample are collected for microbial sequencing and functional evaluation, together with basic health and lifestyle information covering items such as recent dietary patterns, medication and supplement use, antibiotic exposure, illness, travel, and notable lifestyle changes since the previous visit. The exact content and cadence of these routine visits may be adjusted over the course of the study to reflect emerging scientific priorities, participant burden considerations, and operational feasibility, while preserving the core objective of capturing gradual community shifts and flagging transient perturbations occurring between intensive windows.
The intensive sampling mode replicates the original 15-day WeF protocol in full and is scheduled to recur at planned long-interval timepoints. The first intensive follow-up window is conducted approximately six months after completion of the WeF baseline; a second intensive window is planned approximately six months after the first (i.e., approximately one year after the WeF baseline); and additional intensive windows may be conducted at extended intervals thereafter as the cohort is maintained. Each intensive window involves daily collection of stool and saliva samples; collection of representative samples from meals consumed during the period for DNA sequencing of food sources, providing an objective record of dietary intake; and continuous blood glucose monitoring via a wearable CGM device throughout the 15 days. By holding the intensive protocol methodologically consistent with the WeF baseline, each intensive window produces a directly comparable dataset at the level of individual taxa, community structure, dietary signatures, and glycemic responses.
Routine follow-up visits continue in the periods between intensive windows, including after each intensive window has concluded, so that the cohort is observed under a continuous low-frequency framework punctuated by recurring high-frequency snapshots.
Integrating these sampling modes produces a longitudinal dataset that supports several complementary analyses: characterization of the temporal stability of the core microbiota across months and years; assessment of whether the magnitude and structure of day-to-day variability observed at baseline are reproducible at later timepoints; differentiation of intra-individual fluctuations from inter-individual differences across an expanded observation period; identification of seasonal or longer-cycle patterns in microbiome composition; and exploration of how dietary inputs and glycemic patterns relate to microbial dynamics on daily, monthly, and annual scales.
To ensure data integrity and participant safety, the study is overseen by a Data and Safety Monitoring Board and adheres to ethical standards approved by the Westlake University Ethics Committee, consistent with the framework established for the WeF baseline study.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Healthy young adults residing in Hangzhou
Key inclusion criteria (1 listed)
- Participants reside in Hangzhou
Key exclusion criteria (8 listed)
- Refusing or unable to give informed consent
- Participants with chronic gastrointestinal diseases and take daily relevant medications
- Participants with metabolic diseases including diabetes, hypertension and cardiovascular diseases (CVD)
- Participants with craniocerebral trauma, cancer, liver disease, kidney disease, or other critical illness, or history of operation or medication
- Participants with bulimia nervosa, post-traumatic stress disorder (PTSD), chronic anxiety and depression or other critical neuronal disorder or history of relevant medication
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Gut microbiome
Time frame: 3 years
Description: Using qPCR, metagenomics, metabolomics, proteomics, and culturomics, we quantified the composition and absolute abundance of the gut microbiota and characterized its short-term and long-term dynamics.
1 secondary outcome
Continuous blood glucose change over 2 weeks
Time frame: Two weeks after enrollment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Sep 2026.
Related trials for Health Adults
Not yet recruiting
The AYA Oncology Self-care Movement
Acute Lymphobkastic Leukemia, Medication Adherence
Not yet recruiting
Short, Wordless Animated Storytelling to Promote Mental Health Help-Seeking in Young Adults: A U.S. Online Randomized Controlled Trial
Mental Health Help-Seeking
Active, not recruiting
Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant
Transplant;Failure,Kidney, Transplant; Failure, Liver
Active, not recruitingPhase 1
A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
Marburg Virus Disease
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ju-Sheng Zheng, PhD principal investigator
Westlake University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Health Adults and Stability of Microbiome, run by Westlake University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 29 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Gut microbiome (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2026.